comprehensive -WSS

comprehensive

author：hotspot 2025-09-05 11:28:07 - browse：629

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Americans' trust in science, scientist continues decline: Report

Wikipedia

hotspot

WSS

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

The future of health care in the House

The woman behind the Dana Farber

Chan Zuckerberg Biohub Chicago to focus on inflammation

Pregnancy discrimination could be enabled by AI

Histogen: Failed biotech offers rare public look inside

leisure time

comprehensive

entertainment

Medical records are filled with copy

FDA authorizes Novavax’s updated Covid

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Leukemia patients are helped by Syndax's new type of therapy

Medical records are filled with copy

A virus, fished out of a lake, may have saved a man’s life

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Sana to lay off nearly a third of staff, de

The cancer drug shortage isn’t new — and neither are the solutions

What PEPFAR has meant on the ground in Ukraine

focus

Why sickle cell disease is getting the first CRISPR treatment

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

AI models in health care face new federal disclosure requirements

Pregnancy discrimination could be enabled by AI

Was Amgen transparent enough on FDA's concern on cancer drug?

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

knowledge

Wikipedia

hotspot

knowledge